,9 So far, acquired resistance has not been systematically explored in first line setting in NSCLC patients enrolled in clinical trials, and the role of PCT or CTLA-4 inhibitors in influencing acquired resistance upon PD-1/PD-L1 is currently unknown. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.